Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
six
months ended in Dec. 2025,
Pilulka Lekarny AS paidKč0 Mil more to buy back shares than it received from issuing new shares.
It receivedKč0 Mil from issuing more debt.
It paidKč0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedKč0 Mil from paying cash dividends to shareholders.
It receivedKč0 Mil on other financial activities.
In all, Pilulka Lekarny ASspentKč0 Mil on financial activities for the
six
months ended in Dec. 2025.
Pilulka Lekarny AS (XPRA:PINK) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Pilulka Lekarny AS's issuance of stock for the
six
months ended in Dec. 2025 was Kč0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Pilulka Lekarny AS's repurchase of stock for the
six
months ended in Dec. 2025 was Kč0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Pilulka Lekarny AS's net issuance of debt for the
six
months ended in Dec. 2025 was Kč0 Mil.
Pilulka Lekarny AS receivedKč0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Pilulka Lekarny AS's net issuance of preferred for the
six
months ended in Dec. 2025 was Kč0 Mil.
Pilulka Lekarny AS paidKč0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Pilulka Lekarny AS's cash flow for dividends for the
six
months ended in Dec. 2025 was Kč0 Mil.
Pilulka Lekarny AS receivedKč0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Pilulka Lekarny AS's other financing for the
six
months ended in Dec. 2025 was Kč0 Mil.
Pilulka Lekarny AS receivedKč0 Mil on other financial activities.
Pilulka Lekarny AS Cash Flow from Financing Related Terms
Pilulka Lekarny AS Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Pilulka Lekarny AS's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pilulka Lekarny AS Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Pilulka Lekarny AS's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was Kč0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of Kč0 Mil mean?
Pilulka Lekarny AS (XPRA:PINK) has a Cash Flow from Financing of Kč0 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Pilulka Lekarny AS and its competitors.
Is Pilulka Lekarny AS's Cash Flow from Financing too high?
Pilulka Lekarny AS's current Cash Flow from Financing is Kč0 Mil. Overall, Pilulka Lekarny AS has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's Cash Flow from Financing compare to competitors?
Pilulka Lekarny AS's Cash Flow from Financing of Kč0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Healthcare Providers & Services company?
A good Cash Flow from Financing depends on the Healthcare Providers & Services industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Pilulka Lekarny AS and its competitors. Pilulka Lekarny AS's current Cash Flow from Financing is Kč0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč109.33, compared to a current price of Kč116.00 — trading 6.1% above its estimated fair value. The current Cash Flow from Financing is Kč0 Mil. Pilulka Lekarny AS's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current Cash Flow from Financing is Kč0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?
Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be overvalued.
The current stock price of Kč116.00 is trading 6.1% above its estimated GF Value™ of Kč109.33.
GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.
Key valuation signals for XPRA:PINK:
Cash Flow from Financing: Kč0 Mil
GF Value™: Kč109.33 vs. price of Kč116.00 (6.1% above fair value)
No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
47GF Score
Get the complete analysis for XPRA:PINK
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPRA:PINK has been successfully added to your 
